These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18829252)

  • 21. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT; Anzueto A; Fei R; Emmett A; Knobil K; Kalberg C
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
    Hanania NA
    Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision.
    Bateman ED; Feldman C; O'Brien J; Plit M; Joubert JR;
    S Afr Med J; 2004 Jul; 94(7 Pt 2):559-75. PubMed ID: 15283307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly : an appraisal of published evidence.
    Kunisaki KM; Rice KL; Niewoehner DE
    Drugs Aging; 2007; 24(4):303-24. PubMed ID: 17432925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute COPD exacerbations.
    Wedzicha JA; Singh R; Mackay AJ
    Clin Chest Med; 2014 Mar; 35(1):157-63. PubMed ID: 24507843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. State of the Art Compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease.
    O'Donnell DE; Aaron S; Bourbeau J; Hernandez P; Marciniuk D; Balter M; Ford G; Gervais A; Goldstein R; Hodder R; Maltais F; Road J; McKay V; Schenkel J; Ariel A; Day A; Lacasse Y; Levy R; Lien D; Miller J; Rocker G; Sinuff T; Stewart P; Voduc N; Abboud R; Ariel A; Becklake M; Borycki E; Brooks D; Bryan S; Calcutt L; Chapman K; Choudry N; Couet A; Coyle S; Craig A; Crawford I; Dean M; Grossman R; Haffner J; Heyland D; Hogg D; Holroyde M; Kaplan A; Kayser J; Lein D; Lowry J; McDonald L; MacFarlane A; McIvor A; Rea J; Reid D; Rouleau M; Samis L; Sin D; Vandemheen K; Wedzicha JA; Weiss K;
    Can Respir J; 2004; 11 Suppl B():7B-59B. PubMed ID: 15340581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
    Chen AM; Bollmeier SG; Finnegan PM
    Ann Pharmacother; 2008 Dec; 42(12):1832-42. PubMed ID: 18957624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 2007 GOLD Guidelines: a comprehensive care framework.
    Gold PM
    Respir Care; 2009 Aug; 54(8):1040-9. PubMed ID: 19650945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COPD management. Part I. Strategies for managing the burden of established COPD.
    Jenkins C
    Int J Tuberc Lung Dis; 2008 Jun; 12(6):586-94. PubMed ID: 18492322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of stable chronic obstructive pulmonary disease: the GOLD guidelines.
    Lee H; Kim J; Tagmazyan K
    Am Fam Physician; 2013 Nov; 88(10):655-63, 663B-F. PubMed ID: 24364481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exacerbation of chronic obstructive pulmonary disease.
    Ismail TS
    Med J Malaysia; 2009 Sep; 64(3):250-5; quiz 256. PubMed ID: 20527283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
    Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
    Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions.
    Anzueto A
    Am J Med; 2006 Oct; 119(10 Suppl 1):46-53. PubMed ID: 16996899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporating tiotropium into a respiratory therapist-directed bronchodilator protocol for managing in-patients with COPD exacerbations decreases bronchodilator costs.
    Drescher GS; Carnathan BJ; Imus S; Colice GL
    Respir Care; 2008 Dec; 53(12):1678-84. PubMed ID: 19025702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Causal proceeding in chronic obstructive pulmonary disease].
    Chciałowski A; Lubiński W
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():64-9. PubMed ID: 15524021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contemporary issues in the care of patients with chronic obstructive pulmonary disease.
    Urbano FL; Pascual RM
    J Manag Care Pharm; 2005 Jun; 11(5 Suppl A):S2-13; quiz S14-6. PubMed ID: 15934804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.
    Roberts M; Mapel D; Petersen H; Blanchette C; Ramachandran S
    J Med Econ; 2011; 14(6):769-76. PubMed ID: 21942463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED; van Dyk M; Sagriotis A
    Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm.
    Gordon E; Lazarus SC
    J Allergy Clin Immunol; 2009 Nov; 124(5):873-80; quiz 881-2. PubMed ID: 19895979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.